INTRODUCTION
In late December 2019, a group of patients were identified with
pneumonia with unknown aetiology in Wuhan, Hubei, China, and eventually,
severe acute respiratory syndrome - coronavirus 2 (SARS-CoV 2) was
identified by lower respiratory tract samples.1Coronavirus disease 2019 (COVID-2019) outbreak, which infected over 1.5
million people and caused more than 92000 deaths, especially affects the
elderly with comorbid diseases and male population.2,3Symptoms of COVID-19 infection range from asymptomatic disease to acute
respiratory infection and can be potentially fatal in the elderly, over
65 years of age, and those with comorbidity. Transmission routes involve
droplets and close contact. Diagnosis is made by reverse transcription
polymerase chain reaction (RT-PCR) of the sputum, nasopharyngeal swab or
other samples.
Benign prostatic hyperplasia (BPH) is also a worldwide disease directly
related to aging, and is especially common among older men. With
transitioning to an aging society, the incidence and prevalence of
symptomatic BPH increased rapidly.4 Prevalence of BPH
is about 25.3% among men aged 40-79, and more than 50% among men aged
60 and over.5 Considering that COVID-19 pandemic
affecting older and male patients more, it is obvious that the elderly
male population with BPH will be seriously affected by this pandemic.
According to our literature review, there are no studies examining the
clinical features, course and outcomes of COVID-19 disease in patients
diagnosed with BPH.
In our study, we aimed to present our clinical and laboratory
experiences related to patients diagnosed with BPH, also known to be
followed up and treated in our hospital due to COVID-19. We also aimed
to contribute to the information about COVID-19 which is an urgent need.